Related Experiment Video
Updated: May 14, 2026
08:19
Transfer of Manipulated Tumor-associated Neutrophils into Tumor-Bearing Mice to Study their Angiogenic Potential In Vivo
Published on: July 20, 2019
NHE-1: still a viable therapeutic target
1Department of Physiology & Pharmacology, University of Western Ontario, Medical Sciences Building, London, Ontario, Canada N6A 5C1. morris.karmazyn@schulich.uwo.ca
Journal of Molecular and Cellular Cardiology
|February 23, 2013
Summary
Sodium-hydrogen exchanger 1 (NHE-1) inhibition shows promise for protecting the heart from damage and improving recovery after cardiac arrest. Despite clinical trial inconsistencies, NHE-1 inhibition remains a key strategy for treating heart disease.
Area of Science:
- Cardiology
- Molecular Biology
- Pharmacology
Background:
- The sodium-hydrogen exchanger (NHE) family, particularly NHE-1, plays a crucial role in cardiac function and pathology.
- Decades of research support NHE inhibition for myocardial protection against ischemia-reperfusion injury, remodeling, and heart failure.
Purpose of the Study:
- To evaluate the efficacy and safety of NHE-1 inhibition as a therapeutic strategy in cardiovascular diseases.
- To address the discrepancies between experimental findings and clinical outcomes of NHE-1 inhibitors.
Main Methods:
- Review of experimental studies demonstrating cardioprotective effects of NHE-1 inhibitors.
- Analysis of clinical trial data, including outcomes and side effects of NHE-1 inhibitors like cariporide.
- Examination of emerging evidence on NHE-1 inhibition in myocardial remodeling and resuscitation.
Main Results:
- Experimental studies consistently show benefits of NHE-1 inhibition in myocardial protection and attenuation of heart failure.
- Clinical trials, particularly with cariporide, yielded inconsistent results, with some showing poor efficacy and increased cerebrovascular events.
- Despite clinical challenges, NHE-1 inhibition may still be effective for myocardial salvage and has potential in managing remodeling and improving resuscitation outcomes.
Conclusions:
- NHE-1 inhibition remains a promising therapeutic avenue for heart disease, despite past clinical trial limitations.
- Appropriate application of NHE-1 inhibition may still offer significant myocardial salvage and benefits in cardiac remodeling and arrest recovery.
- Further research and refined clinical strategies are needed to optimize the use of NHE-1 inhibitors in cardiovascular medicine.
Related Concept Videos
01:29Pharmacogenomics: Identification of New Drug Targets
Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
01:27Transducer Mechanism: Enzyme-Linked Receptors
Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
Major types that are helpful drug targets include:
02:57Targeted Cancer Therapies
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
There are several types of targeted therapies against specific...
01:11Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
01:26Targets for Drug Action: Overview
Drugs target macromolecules to modify ongoing cellular processes. Primary drug targets include receptors, ion channels, transporters, and enzymes.
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
01:18Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme (ECE). Of...
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme (ECE). Of...